Roles of IGFBP-2 and its evaluation as a biomarker in lung cancer

• Project/Area Number: 21590410
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Human pathology
• Research Institution: The University of Tokyo (2011); Japanese Foundation For Cancer Research (2009-2010)
• Principal Investigator: MIGITA Toshiro 東京大学, 医学部・附属病院, 特任研究員 (20462236)
• Co-Investigator(Kenkyū-buntansha): ISHIKAWA Yuichi 公益財団法人がん研究会がん研究所, 病理部, 部長 (80222975)
• Project Period (FY): 2009 – 2011
• Project Status: Completed (Fiscal Year 2011)
• Budget Amount: ¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000); Fiscal Year 2011: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000); Fiscal Year 2010: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000); Fiscal Year 2009: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
• Keywords: IGFBP-2 / 肺癌 / バイオマーカー

Research Abstract

Secreted IGFBP-2 protein is well known as a regulator of IGF signaling pathway, and regulates tumor growth and survival. The increase in cytoplasmic IGFBP-2 expression is also observed in most cancer cells ; however, the role of intracellular IGFBP-2 remains elusive. We found that IGFBP-2 overexpression reduced procaspase-3 expression in lung cancer cell lines and blocked the camptothecin-mediated apoptosis. LY294002, an inhibitor of phosphatidyl-inositol 3-kinase(PI3K), suppressed lung cancer growth concomitantly with the reduction in IGFBP-2 levels. IGFBP-2 may offer a novel therapeutic target and serve as an anti-apoptotic biomarker for lung cancer.

Research Products

• [Journal Article] Role of insulin-like growth factor binding proteins 2 in lung adenocarcinoma : IGF independentanti-apoptotic effect via caspase-3 (2010)
  • Author(s): Migita T, Narita T, Asaka R, Miyagi E, Nagano H, Nomura K, Matsuura M, Satoh Y, Okumura S, Nakagawa K, Seimiya H, Ishikawa Y
  • Journal Title: Am J Pathol Volume: 176 Pages: 1756-1766
  • Peer Reviewed